



Prof. Dr. Andreas Cerny

Kontakt

Prof. Dr. Andreas Cerny
Switzerland

Publikationen (22)

Moschouri E, Salemme G, Baserga A, Cerny A, Deibel A, Muellhaupt B, Meier M, Bernsmeier C, Ongaro M, Negro F, Grosjean M, Clerc O, Künzler-Heule P, Semela D, Hobi G, Sticckel F, Mathieu A, Mdawar-Bailly E, Faouzi M, Moradpour D, Fraga M. Real-life experience of chronic hepatitis C treatment in Switzerland: a retrospective analysis. *Swiss Med Wkly* 2024; 154:3698.

Ludz C, Stirnimann G, Semela D, Mertens J, Kremer A, Filipowicz Sinnreich M, Sokollik C, Bernsmeier C, Bresson-Hadni S, McLin V, Rock N, Braegger C, Posovszky C, Müller P, Cremer M, De Gottardi A, Galante A, Furlano R, Righini-Grunder F, Becker B, Böhm S, Heyland K, Nydegger A, Limoni C, Vergani D, Mieli-Vergani G, Di Bartolomeo C, Cerny A, Terziroli Beretta-Piccoli B. Epidemiology, clinical features and management of autoimmune hepatitis in Switzerland: a retrospective and prospective cohort study. *Swiss Med Wkly* 2023; 153:40102.

Albrich W, Ghosh T, Ahearn-Ford S, Mikaeloff F, Lunjani N, Forde B, Suh N, Kleger G, Pietsch U, Frischknecht M, Garzoni C, Forlenza R, Horgan M, Sadlier C, Negro T, Pugin J, Wozniak H, Cerny A, Neogi U, O'Toole P, O'Mahony L. A high-risk gut microbiota configuration associates with fatal hyperinflammatory immune and metabolic responses to SARS-CoV-2. *Gut Microbes* 2022; 14:2073131.

Bobzin C, Semmo N, Semela D, Scheidegger C, Rauch A, Negro F, Moradpour D, Mäschi B, Lavanchy D, Künzler-Heule P, Keiser O, Fraga Christinet M, Cerny A, Bruggmann P, Bösiger C, Thurnheer M. Empfehlungen für die Nachsorge von Patientinnen/Patienten mit ausgeheilter Hepatitis C. *Swiss Medical Forum* 2021; 21:184-186.

Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D, Costantini S, Cerny A, Messina P, Di Bartolomeo C, Merlo E, Kolbus N, Voreck A, Mazzucchelli L, Zen Y, Semela D, Mertens J, Stirnimann G, Swiss PBC Cohort Study Group. Primary biliary cholangitis with normal alkaline phosphatase: A neglected clinical entity challenging current guidelines. *J Autoimmun* 2020; 116:102578.

Roelens M, Keiser O, Negro F, Junker C, Semela D, Clerc O, Mullhaupt B, Schmid P, Semmo N, Cerny A, Moradpour D, Bertisch B, Swiss Hepatitis C Cohort Study. All-Cause Mortality and Causes of Death in the Swiss Hepatitis C Cohort Study (SCCS). *Open Forum Infect Dis* 2020; 7:ofaa308.

Goossens N, Semela D, Razavi H, Negro F, Muellhaupt B, Moriggia A, Mertens J, Jornayvaz F, Dufour J, Cerny A, Bellentani S, Estes C. Nonalcoholic fatty liver disease burden - Switzerland 2018-2030. *Swiss Med Wkly* 2019; 149:w20152.

Terziroli Beretta-Piccoli B, Muratori L, Vergani D, Mieli-Vergani G, Moradpour D, Semela D, Semmo N, Mertens J, Cerny A, Melidona L, Tesei C, Silvestri T, Grondona A, Deleonardi G, Di Bartolomeo C, Swiss Hepatitis C Cohort Study. Autoimmune liver serology before and after successful treatment of chronic hepatitis C by direct acting antiviral agents. *J Autoimmun* 2019; 102:89-95.

Terziroli Beretta-Piccoli B, Carbone M, Invernizzi P, Baserga A, Oneta C, Filipowicz Sinnreich M, Giostra E, Bihl F, Kalid-de Bakker C, Sticckel F, Helbling B, Hessler R, Semela D, Cerny A, Stirnimann G, Mertens J. Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland. *Clin Rev Allergy Immunol* 2017

Gauthiez E, Moradpour D, Mullhaupt B, Negro F, Semela D, Semmo N, Villard J, Bibert S, Bochud P, Malinverni R, Heim M, Habfast-Robertson I, Rüeger S, Kutalik Z, Aubert V, Berg T, Cerny A, Gorgievski M, George J, Swiss Hepatitis C Cohort Study. A systematic review and meta-analysis of HCV clearance. *Liver Int* 2017; 37:1431-1445.

Terczyńska-Dyla E, Moradpour D, Mullhaupt B, Negro F, Santoro R, Semela D, Semmo N, Swiss Hepatitis C Cohort Study Group, Heim M, Bochud P, Mangia A, Malinverni R, Bibert S, Duong F, Krol I, Jørgensen S, Collinet E, Kutalik Z, Aubert V, Cerny A, Kaiser L, Hartmann R. Corrigendum: reduced IFN λ 4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. *Nat Commun* 2015; 6:7280.

Terczyńska-Dyla E, Moradpour D, Mullhaupt B, Negro F, Santoro R, Semela D, Semmo N, Swiss Hepatitis C Cohort Study Group, Heim M, Bochud P, Mangia A, Malinverni R, Bibert S, Duong F, Krol I, Jørgensen S, Collinet E, Kutalik Z, Aubert V, Cerny A, Kaiser L, Hartmann R. Reduced IFN λ 4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. *Nat Commun* 2014; 5:5699.

Lange C, Negro F, Semela D, Kutalik Z, Müller T, Spengler U, Berg T, Chayama K, Moradpour D, Bochud P, Hiroshima Liver Study Group, Mullhaupt B, Malinverni R, Heim M, Miki D, Ochi H, Nischalke H, Bojunga J, Bibert S, Morikawa K, Gouttenoire J, Cerny A, Dufour J, Gorgievski-Hrisoho M, Swiss Hepatitis C Cohort Study Group. Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development. *PLoS one* 2013; 8:e64053.

Lange C, Bochud P, Kutalik Z, Moradpour D, Semela D, Negro F, Mullhaupt B, Malinverni R, Kaiser L, Heim M, Cerny A, Cellerai C, Dufour J, Bibert S, Swiss Hepatitis C Cohort Study Group. Comparative genetic analyses point to HCP5 as susceptibility locus for HCV-associated hepatocellular carcinoma. *J Hepatol* 2013; 59:504-9.

Kuske L, Dufour J, Cerny A, Malinverni R, Heim M, Malé P, Moradpour D, Semela D, Negro F, Mullhaupt B, Mensen A, Swiss Hepatitis C Cohort Study. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma. *Swiss Med Wkly* 2012; 142:w13651.

Patin E, Stewart G, Booth D, George J, Casanova J, Bréchet C, Rice C, Talal A, Jacobson I, Bourlière M, Theodorou I, Poynard T, Negro F, Pol S, Bochud P, Abel L, Swiss Hepatitis C Cohort Study Group, International Hepatitis C Genetics Consortium, Suppiah V, Martinetti G, Hirsch H, Kutalik Z, Guergnon J, Bibert S, Nalpas B, Jouanguy E, Munteanu M, Bousquet L, Argiro L, Halfon P, Boland A, Mullhaupt B, Semela D, Dufour J, Heim M, Moradpour D, Cerny A, Malinverni R, French ANRS HC EP 26 Genoscan Study Group. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. *Gastroenterology* 2012; 143:1244-52.e1-12.

Gonvers J, Troillet N, Negro F, Monnat M, Malinverni R, Dutoit V, Dufour F, Chuard C, Chave J, Cerny A, Borovicka J, Bernasconi E, Genné D, Mullhaupt B, Cavassini M, Heim M, Oneta C. Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study. *Swiss Med Wkly* 2010; 140:w13055.

Rauch A, Hirschel B, Malinverni R, Moradpour D, Mullhaupt B, Witteck A, Beckmann J, Berg T, Bergmann S, Negro F, Telenti A, Bochud P, Swiss Hepatitis C Cohort Study, Heim M, Günthard H, Furrer H, Kutalik Z, Descombes P, Cai T, di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour J, Swiss HIV Cohort Study. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. *Gastroenterology* 2010; 138:1338-45, 1345.e1-7.

Schwendener R, Ludewig B, Cerny A, Engler O. Liposome-based vaccines. *Methods in molecular biology* (Clifton, N.J.) 2010; 605:163-75.

Bochud P, Negro F, Francioli P, Malinverni R, Cerny A, Moradpour D, Heim M, Borovicka J, Mullhaupt B, Dufour J, Bochud M, Overbeck K, Cai T, Swiss Hepatitis C Cohort Study Group. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. *Journal of hepatology* 2009; 51:655-66.

Ciuffreda D, Bernasconi E, Monnat M, Cerny A, Chuard C, Borovicka J, Mentha G, Pascual M, Gonvers J, Pantaleo G, Oneta C, Malinverni R, Comte D, Cavassini M, Giostra E, Buhler L, Perruchoud M, Heim M, Battegay M, Genné D, Mullhaupt B, Dutoit V. Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication. *European journal of immunology* 2008; 38:2665-77.

Helbling B, Renner E, Meyer-Wyss B, Esteban A, Mullhaupt B, Dinges S, Wilhelmi M, Gonvers J, Borovicka J, Cerny A, Knöpfli M, Stamenic I, Jochum W, Swiss Association for the Study of the Liver (SASL). HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin. *Journal of viral hepatitis* 2006; 13:762-9.

Projekte (1)

CRiPSI/CRiPSI-X: Covid-19 Risk Prediction in Swiss ICUs-Trial/Extension

Klinische Forschung - 01.08.2020 - 31.08.2022

Automatisch geschlossen

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch